Revolutionary X4™ technology combines advanced proprietary controller algorithms with world’s largest-capacity monolithic 64 Gigabit Flash chip Volume shipments of SDHC™ and Memory Stick PRO™ cards employing X4 technology began in September 2009 MILPITAS, Calif.--(BUSINESS WIRE)--Oct. 13, 2009-- SanDisk Corporation (NASDAQ:SNDK), the global leader in flash memory cards, today announced it has begun production shipments of flash memory cards based on the company’s advanced X4 flash memory technology. This innovative new technology holds four bits of data in each memory cell, twice as many as the cells in conventional multi-level cell (MLC) NAND (2-bits-per-cell) memory chips. Based on 43-nanometer (nm) process technology, the 64-gigabit (Gb) NAND flash chip is the highest-density single-die memory device in the world to enter production. SanDisk is shipping 8 gigabyte (GB)1and 16GB SDHC cards as well as 8GB and 16GB Memory Stick PRO Duo™ cards using X4 technology. “The development and commercialization of X4 technology represents an important milestone for the flash storage industry,” said Sanjay Mehrotra, president and chief operating officer, SanDisk.

October 26th , 2009 - HYPERLINK "http://championsbiotechnology.com/"Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University’s wholly owned technology transfer company. The licensing agreement encompasses the development and commercialization of TAR-1, a single-chain antibody fragment in preclinical development that may have an advantage in treating cancer patients because of its high specificity and affinity to binding mutant p53 protein.

JERUSALEM, Sept. 23, 2009 (GLOBE NEWSWIRE) -- Following our previous press release (published September 14th, 2009) announcing that BL-1020 has successfully met its primary and secondary efficacy endpoints from the phase 2b EAGLE (Effective Anti-psychosis via GABA Level Enhancement) trial, we are pleased to report positive final results regarding the effects of BL-1020 on cognition.

Following the debate on the allocation of public funding to the new Biotech Fund, Yissum CEO Yaacov Michlin explains the advantage of investing in biotechnology research

The country's first interdisciplinary center for developing drugs will be opened this week by the Hebrew University of Jerusalem on the Ein Kerem campus of its School of Pharmacy - thereby utilizing the talents and ideas of a wide variety of campus scientists and attracting financial support from donors and the pharmaceutical industry

According to the terms of the agreement, Roche has selected six promising research projects in the fields of stem cells, biomarkers, and novel molecules for the treatment of metabolic diseases, initiated by Hebrew University researchers

JERUSALEM, June 6 (Reuters) - Israeli drug development company BiolineRX said on Monday that New Jersey-based Ikaria Holdings Inc had agreed to pay $285 million for a license to develop and market its BL-1040 drug for heart attack patients.

Deutsche Telekom will be doubling its investment on research in Israel, company CEO Ren? Obermann told TheMarker. The lion's portion of that investment will apparently go to the German giant's research lab at Ben-Gurion University of the Negev, which has been operational for three years.